Table 1 Clinical characteristics of 4 groups according to TR severity
Baseline characteristics | Trace TR (n = 54) | Mild TR (n = 81) | Moderate TR (n = 59) | Severe TR (n = 13) | P |
|---|---|---|---|---|---|
Age (years) | 48.5 ± 13.9 | 51 (33,61) | 50.3 ± 14.5 | 45.8 ± 14.7 | 0.701 |
Sex (male, %) | 44.4% | 44.4% | 32.2% | 46.2% | 0.442 |
BSA (m2) | 1.7 (1.6–1.9) | 1.7 ± 0.2 | 1.6 (1.5–1.7) | 1.7 ± 0.2 | 0.936 |
III-IV Class % (WHO Heart function) | 24/54, 44.4% | 42/81, 51.9% | 36/59, 61.0% | 7/13, 53.4% | 0.370 |
6MWD (m) | 403.4 ± 110.2 | 368 ± 97.1 | 365.1 ± 79.9 | 328 ± 164.6 | 0.772 |
NT-proBNP | 229.0 (125.0, 681) | 565.5* (262.5, 1046.3) | 1438.5*♦ (636.5,2426.8) | 1621.0*♦ (554.3,3063.3) | p < 0.001 |
PH medical treatment | |||||
Phosphodiesterase type-5 inhibitors | 22/54,40.7% | 19/81,23.5 | 13/59,22.0% | 4/13,30.8% | 0.090 |
Endothelin receptor antagonists | 10/54,18.5% | 19/81,23.5% | 14/59,23.7% | 3/13,23.1% | 0.900 |
Soluble guanylate cyclase stimulator | 3/54, 5.6% | 5/81, 6.2% | 3/59, 5.1% | 2/13,15.4% | 0.567 |
Diuretics | 44/54, 81.5% | 72/81,88.9% | 53/59,89.8% | 12/13,92.3% | 0.477 |